Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraprostatic BOTOX for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
2005-004281-17Phase 2Completed
- Sponsor
- Allergan
- Start
- Apr 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botulinum toxin type A in benign prostatic hyperplasia (BPH) and Micturition disorder (4 arms), sponsored by Allergan. Primary endpoint: Change in International Prostate Symptom Score at 12 weeks. Started Apr 2006; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
benign prostatic hyperplasia (BPH)Micturition disorder
Beyond the preview
Go deeper on 2005-004281-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004281-17.